Table 3 Risk of bias assessment on MACE in eligible RCTs
Domain | Mainland China | United States | ||||
|---|---|---|---|---|---|---|
Non-redundant RCTs | Redundant RCTs | Total | Non-redundant RCTs | |||
Partially redundant RCTs | Entirely redundant RCTs | Total | ||||
No. of RCTs reporting MACE | 151 | 93 | 297 | 390 | 541 | 4 |
Random sequence generation | Â | |||||
 Low Risk | 4 (2.6) | 7 (7.5) | 79 (26.6) | 86 (22.1) | 90 (16.6) | 1 (25.0) |
 High risk | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Unclear risk | 147 (97.4) | 86 (92.5) | 218 (73.4) | 304 (77.9) | 451 (83.4) | 3 (75.0) |
Allocation concealment | Â | |||||
 Low risk | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (50.0) |
 High risk | 0 (0.0) | 1 (1.1) | 14 (4.7) | 15 (3.8) | 15 (2.8) | 0 (0.0) |
 Unclear risk | 151 (100.0) | 92 (98.9) | 283 (95.3) | 375 (96.2) | 526 (97.2) | 2 (50.0) |
Blinding of participants and researchers | Â | |||||
 Low risk | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 High risk | 147 (97.4) | 92 (98.9) | 292 (98.3) | 384 (98.5) | 531 (98.2) | 3 (75.0) |
 Unclear risk | 4 (2.6) | 1 (1.1) | 5 (1.7) | 6 (1.5) | 10 (1.8) | 1 (0.0) |
Blinding of outcome assessment | Â | |||||
 Low risk | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) |
 High risk | 148 (98.0) | 92 (98.9) | 292 (98.3) | 384 (98.5) | 532 (98.3) | 2 (50.0) |
 Unclear risk | 3 (2.0) | 1 (1.1) | 5 (1.7) | 6 (1.5) | 9 (1.7) | 1 (25.0) |